Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0NUDUN
ADC Name	BT062-SPDB-DM4
Synonyms	BT062 SPDB DM4 Click to Show/Hide
Drug Status	Investigative
Indication	In total 1 Indication(s) Multiple myeloma [ICD11:2A83] Investigative
Drug-to-Antibody Ratio	3.5
Structure
	3D MOL	2D MOL
Antibody Name	Indatuximab		Antibody Info
Antigen Name	Syndecan-1 (SDC1)		Antigen Info
Payload Name	Mertansine DM4		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)		Linker Info
Conjugate Type	Lysine residue on the antibody is conjugated via an amide bond to the linker-payload moiety.
Combination Type	Ravtansine

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 3 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 56.56	%	MOLP-8 cells	Plasma cell myeloma
Tumor Growth Inhibition value (TGI)	≈ 87.92	%	MOLP-8 cells	Plasma cell myeloma
Tumor Growth Inhibition value (TGI)	≈ 95	%	MOLP-8 cells	Plasma cell myeloma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 56.56% (Day 26)
Method Description	The inhibitory activity of nBT062-SPDB-DM4 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated with 100g/kg.
In Vivo Model	SCID-hu MM model
In Vitro Model	Plasma cell myeloma	MOLP-8 cells	CVCL_2124
Experiment 2 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 87.92% (Day 26)
Method Description	The inhibitory activity of nBT062-SPDB-DM4 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated with 250g/kg.
In Vivo Model	SCID-hu MM model
In Vitro Model	Plasma cell myeloma	MOLP-8 cells	CVCL_2124
Experiment 3 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95.00% (Day 26)
Method Description	The inhibitory activity of nBT062-SPDB-DM4 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated with 450g/kg.
In Vivo Model	SCID-hu MM model
In Vitro Model	Plasma cell myeloma	MOLP-8 cells	CVCL_2124

References

Ref 1	The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res. 2009 Jun 15;15(12):4028-37.